# Agentic Commerce And Provenance

BellLabs should treat purchasing as the visible tip of a much larger reasoning process. The product, service, lab test, device, supplement, or treatment is not the main artifact. The main artifact is the decision package: the user's goal, the evidence considered, the alternatives compared, the risks accepted, the uncertainties left open, and the follow-up plan.

## Agentic Cart

The agentic cart is a cart plus a research dossier.

Each cart item should include:

- Product, service, treatment, lab test, device, ingredient, or protocol component.
- Vendor, listing, price, availability, purchasing constraints, and checkout path.
- User goal, protocol step, or research question that caused the item to enter the cart.
- Evidence bundle with claims, sources, studies, practitioner references, and conflicts.
- Personalization notes based on user goals, biomarkers, preferences, and constraints.
- Safety notes, contraindications, interactions, and clinician-review triggers.
- State machine for the lifecycle: considered, shortlisted, approved, purchased, awaiting fulfillment, completed, report uploaded, reviewed, integrated, abandoned.

The user should be able to click a link or icon beside any cart item and see the exact notes, reports, and references that supported the decision.

## Product Decision Ledger

BellLabs should maintain a durable decision ledger. This ledger is useful even when the platform cannot complete checkout directly.

The ledger should store:

- Why the item was considered.
- Which agent, workflow, user action, guide, or protocol introduced it.
- Which alternatives were rejected and why.
- Which sources were decisive.
- Which claims were accepted, disputed, or left unresolved.
- What the user actually did.
- What happened afterward.

The ledger lets a user reconstruct a health decision months later. It also gives the system training and evaluation material, with consent, for better future recommendations and research workflows.

## Commerce Integration Levels

BellLabs should support multiple integration levels because the biotech commerce ecosystem will be uneven.

### Level 0: External Link

The platform links to the vendor and records the decision package. The user completes checkout manually. The agent later asks for status updates.

### Level 1: Assisted Checkout

The platform pre-fills known information, generates instructions, monitors reminders, and tracks purchase state, but the final checkout happens externally.

### Level 2: API Checkout

The vendor exposes an API for availability, pricing, cart creation, order placement, fulfillment status, or lab report delivery.

### Level 3: Agentic Commerce

The vendor supports agent-mediated purchase protocols, authenticated user approval, machine-readable policies, structured product metadata, and post-purchase webhooks.

### Level 4: BellLabs Native Marketplace

The vendor lists directly in BellLabs with structured claims, SKUs, evidence, safety caveats, fulfillment integrations, and policy controls.

## Evidence Bundle Model

Every commerce decision should connect to an evidence bundle. An evidence bundle should contain:

- Claims: what is being asserted.
- Sources: where each claim came from.
- Entities: products, companies, ingredients, biomarkers, mechanisms, studies, people, protocols, and conditions.
- Confidence: evidence strength, source quality, recency, and reproducibility.
- Contradictions: claims that disagree or have unresolved context.
- User relevance: why this evidence matters for this user.
- Actionability: what decision the evidence supports.

This turns shopping into an inspectable research process.

## Example: TruDiagnostic Biomarker Panel

1. The user explores Bryan Johnson's public longevity protocol.
2. BellLabs maps TruDiagnostic to a lab testing company, relevant products, listed panels, biomarkers, sample requirements, studies, claims, and public practitioner references.
3. The agent compares the panel to other available testing options.
4. The user places TruDiagnostic into the agentic cart.
5. The cart item links to the evidence bundle and the user's goal, such as "establish baseline biological age and methylation markers before starting a 12-week protocol."
6. The platform records the order state and waits.
7. The user later uploads the report.
8. BellLabs ingests biomarkers, updates the dashboard, links results to the protocol, and creates follow-up research tasks.

## Example: Evenity Testimonial Research

A user considering osteoporosis treatment may want information beyond clinical summaries. BellLabs should allow the user to start a research campaign for real-world testimonials while clearly separating anecdote from clinical evidence.

The campaign might gather:

- Patient forum posts.
- Video transcripts.
- Case reports.
- Adverse event discussions.
- Clinician explainers.
- Regulatory label information.
- Clinical trial outcomes.

The output should label source type, bias risk, patient similarity, uncertainty, and whether the information should trigger a clinician discussion.

## Incentives And Transparency

If BellLabs earns affiliate revenue, marketplace fees, referral fees, sponsored placement, data licensing revenue, or vendor integration fees, those incentives must be exposed in the product surface. Trust will collapse if the user cannot tell why an item appears.

Recommended policy:

- Rank by user fit and evidence first.
- Label commercial relationships beside affected listings.
- Preserve rejected alternatives and reasoning.
- Keep evidence bundles inspectable.
- Allow users to filter out sponsored or affiliate-linked products.

## Commerce Safety Gates

BellLabs should define high-risk categories that require stronger friction:

- Prescription drugs or biologics.
- Treatments with serious adverse event profiles.
- Interventions involving pregnancy, pediatrics, cancer, cardiovascular disease, psychiatric illness, or immunosuppression.
- Invasive procedures.
- Lab results that indicate urgent medical concern.
- Conflicts with the user's medications, diagnoses, allergies, or clinician instructions.

The system can still educate and organize evidence, but purchase facilitation and protocol activation should require stronger warnings, human confirmation, and sometimes clinician involvement.
